CVRx (CVRX) Cash from Operations Growth (3y) (2023 - 2026)
CVRx (CVRX) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.00 Bn | 175.71 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.69 Bn | 125.81 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.39 Bn | 66.93 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.97 Bn | 44.30 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.00 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.21 Bn | 27.09 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | 0.50% |
| 10 | CVRx | 129.41 Mn | 57.10 Mn | 12.88 Mn | -5.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.88% |
| Dec 31, 2025 | 3.45% |
| Sep 30, 2025 | 4.35% |
| Jun 30, 2025 | 7.71% |
| Mar 31, 2025 | -6.25% |
| Dec 31, 2024 | -4.51% |
| Sep 30, 2024 | -4.15% |
| Jun 30, 2024 | -15.00% |
| Mar 31, 2024 | -29.32% |
| Dec 31, 2023 | -24.28% |
| Sep 30, 2023 | -16.36% |